Trials / Completed
CompletedNCT04707573
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
A Phase 2A Single Dose, Open Label Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Akebia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose of Vadadustat.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vadadustat | oral capsules |
Timeline
- Start date
- 2010-07-08
- Primary completion
- 2010-09-24
- Completion
- 2010-09-24
- First posted
- 2021-01-13
- Last updated
- 2022-06-28
- Results posted
- 2022-05-17
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04707573. Inclusion in this directory is not an endorsement.